What is the initial management for bradycardia in Advanced Cardiovascular Life Support (ACLS)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 26, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Initial Management for Bradycardia in ACLS

The initial management for symptomatic bradycardia in ACLS is to administer atropine 0.5-1 mg IV, which can be repeated every 3-5 minutes to a maximum total dose of 3 mg. 1, 2

Assessment and Initial Steps

  • First, evaluate if bradycardia is causing symptoms or hemodynamic compromise (altered mental status, ischemic chest discomfort, acute heart failure, hypotension, or other signs of shock) 2
  • Maintain patent airway and assist breathing as necessary 2
  • Provide supplemental oxygen if the patient is hypoxemic 2
  • Establish cardiac monitoring to identify rhythm, monitor blood pressure, and measure oxygen saturation 2
  • Establish IV access for medication administration 2
  • Obtain a 12-lead ECG if available 2
  • Identify and treat underlying reversible causes 2

Pharmacological Management

First-Line Treatment: Atropine

  • Administer atropine 0.5-1 mg IV for symptomatic bradycardia 1
  • Repeat every 3-5 minutes as needed up to a maximum total dose of 3 mg 1, 2
  • Doses of atropine <0.5 mg may paradoxically result in further slowing of heart rate and should be avoided 1
  • Atropine reverses decreases in heart rate, systemic vascular resistance, and blood pressure mediated by parasympathetic (cholinergic) activity 1, 3
  • Atropine is most effective for sinus bradycardia occurring within 6 hours of onset of symptoms of acute MI 1

If Bradycardia Persists Despite Atropine

  • Initiate IV infusion of β-adrenergic agonists 1, 2:
    • Dopamine: 5-20 mcg/kg/min IV, starting at 5 mcg/kg/min and increasing by 5 mcg/kg/min every 2 minutes 1
    • Epinephrine: 2-10 mcg/min IV or 0.1-0.5 mcg/kg/min IV titrated to desired effect 1
    • Isoproterenol: 20-60 mcg IV bolus followed by doses of 10-20 mcg, or infusion of 1-20 mcg/min based on heart rate response 1

Pacing Considerations

  • Consider transcutaneous pacing (TCP) in unstable patients who do not respond to atropine 1, 2
  • TCP is a temporizing measure and can be painful in conscious patients 1
  • Prepare for transvenous pacing if the patient does not respond to drugs or TCP 1
  • Indications for temporary pacing include 1:
    • Sinus bradycardia with symptoms of hypotension unresponsive to drug therapy
    • Symptomatic bradycardia not responsive to atropine
    • Bilateral bundle branch block
    • New or indeterminate age bifascicular block with first-degree AV block
    • Mobitz type II second-degree AV block

Special Considerations

Type of AV Block

  • Atropine is likely to be effective in sinus bradycardia, conduction block at the level of the AV node, or sinus arrest 1, 2
  • Atropine may be ineffective in type II second-degree or third-degree AV block with new wide-QRS complex where the block is likely in non-nodal tissue 1, 2
  • For these cases, consider immediate pacing rather than multiple doses of atropine 1

Specific Clinical Scenarios

  • Avoid atropine in heart transplant patients without evidence of autonomic reinnervation, as it may cause paradoxical high-degree AV block 1
  • Use atropine cautiously in inferior myocardial infarction as increased heart rate may worsen ischemia or increase infarction size 1, 2
  • For bradycardia associated with beta-blocker or calcium channel blocker overdose, consider glucagon (3-10 mg IV with infusion of 3-5 mg/h) 1
  • For BRASH syndrome (Bradycardia, Renal failure, AV nodal blockade, Shock, and Hyperkalemia), treatment should focus on correcting hyperkalemia and improving renal function 4, 5

Potential Complications and Pitfalls

  • Atropine administration should not delay implementation of external pacing for patients with poor perfusion 1, 2
  • Excessive doses of atropine (>3 mg) may cause central anticholinergic syndrome, including confusion, agitation, and hallucinations 2
  • Dosages of dopamine >20 mcg/kg/min may result in vasoconstriction or arrhythmias 1
  • Monitor for potential development of ischemic chest pain with isoproterenol 1

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Management of Symptomatic Bradycardia

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Two Cases of BRASH Syndrome: A Diagnostic Challenge.

European journal of case reports in internal medicine, 2022

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.